GCM
PCVX icon

Graham Capital Management’s Vaxcyte PCVX Stock Holding History

Graham Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,082
Closed -$361K – 1251
2023
Q3 		$361K Sell
7,082
-3,467
-33% -$171K 0.01% 659
2023
Q2 		$527K Buy
+10,549
New +$500K 0.02% 543

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's PCVX Position: Q4 2023 in Review

Graham Capital Management sold out of Vaxcyte (PCVX) in Q4 2023, closing a stake of 7,082 shares — an estimated $361K sold.

Graham Capital Management first reported a position in PCVX in Q2 2023 and held it in 2 quarters. The position peaked at $527K in Q2 2023. 223 funds tracked by Wall St. Rank hold PCVX as of Q4 2023.

  • Graham Capital Management reported no remaining Vaxcyte position as of Q4 2023 after selling out during the quarter.
  • Graham Capital Management sold 7,082 Vaxcyte shares in Q4 2023, an estimated $361K.
  • Graham Capital Management first reported a position in Vaxcyte in Q2 2023 and held it in 2 quarters.
  • Graham Capital Management's Vaxcyte position peaked at $527K in Q2 2023.
  • 223 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2023.

Based on Graham Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.